Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia

Atsuhito Ushiki, Yoshitaka Yamazaki, Mineyuki Hama, Masanori Yasuo, Masayuki Hanaoka, Keishi Kubo

First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto City, Nagano Prefecture 390-0316, Japan
Department of Infectious Disease, Suzaka Hospital, 1332 Suzaka City, Nagano Prefecture 382-0091, Japan
Endoscopic Examination Center, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto City, Nagano Prefecture 390-0316, Japan

Background: Patients with slowly progressive idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis, often deteriorate, thus suggesting that the clinical course may be unpredictable. Such episodes are termed acute exacerbation of idiopathic interstitial pneumonia. The etiology of an acute exacerbation of idiopathic interstitial pneumonia is unknown. In this study, we tested the hypothesis that an acute exacerbation of idiopathic interstitial pneumonia is induced by respiratory viral infections.

Methods: Bronchoalveolar lavage fluid obtained from patients with an acute exacerbation of idiopathic interstitial pneumonia was tested for viral nucleic acid using polymerase chain reaction.

Results: Only 1 of the 14 patients with an acute exacerbation of idiopathic interstitial pneumonia was tested for viral nucleic acid using polymerase chain reaction.

Conclusions: Most cases with an acute exacerbation of idiopathic interstitial pneumonia are not caused by a viral infection.

© 2013 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Abbreviations: IIP, idiopathic interstitial pneumonia; IPF, interstitial pulmonary fibrosis; BAL, bronchoalveolar lavage; Sd, standard deviation; BALF, bronchoalveolar lavage fluid; PCR, polymerase chain reaction; DNA, deoxyribonucleic acid; RNA, ribonucleic acid; RT, reverse transcriptase; CMV, cytomegalovirus; IL, interleukin

*Corresponding author. Tel.: +81 263 37 2631; fax: +81 263 36 3722.
E-mail addresses: atsuhito@shinshu-u.ac.jp (A. Ushiki), yamazaki-yoshitaka@pref-nagano-hosp.jp (Y. Yamazaki), jco515.mc@yahoo.co.jp (M. Hama), yasumasa@shinshu-u.ac.jp (M. Yasuo), masayuki@shinshu-u.ac.jp (M. Hanaoka), keishik@shinshu-u.ac.jp (K. Kubo).
1. Introduction

Idiopathic interstitial pneumonia (IIP) is a group of diffuse parenchymal lung diseases with an unknown cause. IIP includes the entities of idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease, desquamative interstitial pneumonia, and lymphocytic interstitial pneumonia [1]. IPF is the most common form of IIP and is diagnosed on the basis of clinical characteristics such as high-resolution chest computed tomography findings, pulmonary function tests, and physiological findings [2]. If patients with IIP do not fulfill these criteria, surgical lung biopsies are necessary to classify the IIP as a particular type. The histopathological finding termed usual interstitial pneumonia of IPF involves a heterogeneous appearance at low magnification with alternating areas of normal lung tissue, interstitial inflammation, fibrosis, and honeycomb changes [2].

Although IPF is a gradually progressive disease, some patients experience acute respiratory deterioration, suggesting that the clinical course may be unpredictable. Such episodes are termed an acute exacerbation of IPF [3]. A similar process of acute, unexplained respiratory deterioration occurs in patients with IIP [4]. The generic term for such episodes and an acute IPF exacerbation is an acute exacerbation of IIP.

Although a previous report showed that reducing steroid doses for IPF treatment, bronchoalveolar lavage (BAL), and surgical treatment [5] could induce an acute exacerbation of IPF, the etiology of the disease is unknown. It is unclear whether respiratory viral infections might induce an acute IIP exacerbation. An acute IIP exacerbation has similar clinical symptoms and high-resolution computed tomography chest findings to that of viral pneumonia, with a poor sensitivity to the standard methods of viral detection.

In this study, we tested the hypothesis that an acute IIP exacerbation is induced by respiratory viral infections. We collected bronchoalveolar lavage fluid (BALF) from patients with an acute IIP exacerbation and used polymerase chain reaction (PCR) to detect respiratory viruses.

2. Material and methods

2.1. Patients

Patients with an acute IIP exacerbation were admitted to Shinshu University Hospital between April 2007 and March 2011. The criteria for an IIP exacerbation were as follows: (1) unexplained worsening or development of dyspnea within 30 days; (2) the presence of new, bilateral pulmonary ground-glass abnormalities, consolidation superimposed on a background of a reticular or honeycomb pattern on chest computed tomography, or both; (3) acute respiratory symptoms; (4) no pathogenic bacteria in the BALF; and (5) exclusion of alternative causes (e.g., left heart failure and pulmonary embolism) [6]. If a patient previously or concurrently fulfilled the consensus criteria of the American Thoracic Society/European Respiratory Society for a diagnosis of IPF [2], the patient was diagnosed with an exacerbation of IPF. Written informed consent was obtained from all patients before sample collection. This study was approved by the Ethics Committee of the Shinshu University School of Medicine (approval number; 2235, approval date: March 4, 2013).

2.2. Sample collection and processing

In all cases, bronchoscopy was performed as part of the clinical evaluations. In cases of respiratory failure, we performed bronchoscopy with oxygen supplementation or the use of non-invasive ventilation. BAL was performed in a segment or subsegment of the right middle lobe or lingual region with 150 mL of sterile saline instilled. Subsequently, the BALF was analyzed for the white blood cell count and differential and virus separation. The increase in the percentage of each white blood cell was assessed based on the following American Thoracic Society guidelines: increases in the percentages of lymphocytes, neutrophils, and eosinophils were ≥15%, ≥3%, and ≥1% [7], respectively. Viral separation was performed at SRL (Tokyo, Japan). The BALF samples used for PCR were stored at −70 °C until ready for processing. Total deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) were extracted from 200 μL of each BALF sample using the QIAamp MinElute Virus Spin kit (Qiagen, Tokyo, Japan).

2.3. cDNA synthesis

The cDNA synthesis was performed using the Cycleave PCR kit (Takara Bio, Tokyo, Japan) according to the manufacturer’s protocol [8]. In summary, reverse transcriptase (RT) was performed in an Eppendorf tube containing 20 μL of a reaction mixture comprising a 1-μg aliquot of the DNA/RNA sample. The reaction mixture consisted of 10 μL of 2× RT Buffer Mix containing buffer, dNTP mixture, and a random primer (Takara Bio, Shiga, Japan) along with 1 μL of PrimeScript RT Enzyme MIX 1 containing PrimeScript RTase and RNase inhibitor (Takara Bio, Shiga, Japan). The final volume of the reaction mixture was adjusted to 20 μL with the addition of DNase- and RNase-free H2O. The RT reaction was carried out at 37 °C for 15 min, and deactivation of RTase was carried out at 85 °C for 4 s using a thermal cycler 2700 (Life Technologies, Tokyo, Japan).

We performed BAL for 3 patients with pneumonia caused by the 2009 pandemic H1N1 influenza, treated the BALF, and synthesized the cDNA according to the above methods in order to examine the validity of the techniques. All 3 BALF samples were positive by PCR for the 2009 pandemic H1N1 influenza.

2.4. PCR analysis

A PCR analysis was also performed using the Cycleave PCR kit (Takara Bio, Tokyo, Japan) according to the manufacturer’s protocol. This kit is able to detect 11 respiratory infection viruses, including respiratory syncytial virus (RSV)-A, RSV-B, human parainfluenza virus 1, human parainfluenza virus 2, human parainfluenza virus 3, human metapneumovirus, influenza A virus, influenza B virus, human adenovirus, human bocavirus, and human rhinovirus. The reaction mixture consisted of 2 μL of each RT mixture, 12.5 μL of 2×
Cycleave PCR Reaction Mix containing buffer and dNTP mixture (Takara Bio, Shiga, Japan) and 2 μL of each primer/probe. The final volume of the mixture was adjusted to 25 μL with the addition of DNase- and RNase-free H2O. In addition to BALF, the reaction mixture was made using each viral positive control in the Cycleave PCR kit, with human rhinovirus cDNA obtained from a non-specific intestinal pneumonia on the basis of high-resolution chest computed tomography findings. Before exacerbation, amplification was started at 95 °C for 10 s, followed by 40 cycles of PCR using a thermal cycler 2700 (Life Technologies, Tokyo, Japan) as follows: 95 °C for 5 s, 55 °C for 15 s, and 72 °C for 20 s. The PCR for cytomegalovirus (CMV) DNA was performed at SRL (Tokyo, Japan). For positive cases, we performed CMV antigenemia while utilizing the patients’ peripheral blood.

3. Results

3.1. Results

The patient characteristics are shown in Table 1. Fourteen patients (11 men) with an exacerbation of IIP were recruited. Seven patients fulfilled the criteria of IPF. The other patients were suspected of having a nonspecific interstitial pneumonia on the basis of high-resolution chest computed tomography findings. Before exacerbation, only 1 patient was treated with immunosuppressive therapy. The other patients were not treated with IIP-specific drugs such as immunosuppressive drugs, pirfenidine, and inhaled N-acetylcysteine. In most patients, the white blood cell count, C-reactive protein level, and KL-6 level were increased (mean ± standard deviation [SD]; 8862.1 ± 2476.3/μL, 6.29 ± 4.36 mg/dL, and 1625 ± 1315 U/mL, respectively).

The BALF findings are shown in Table 2. BAL was performed in all patients with 150 mL of sterile saline. In most patients, the total cell count was increased (mean ± SD; 5.24 ± 1.86 x 10^7/mL). The percentage of lymphocytes was increased in 9 patients. The percentage of neutrophils was increased in 12 patients. The percentage of eosinophils was increased in 10 patients. Viral separation was performed in 8 patients, and no viruses were separated in any of the 8 patients. All positive viral controls and human rhinovirus cDNAs obtained from humans were positive for respiratory viruses. The BALF was positive for RSV-B in 1 case (patient 7). Although the BALF was positive for CMV in 2 cases (patients 12 and 14) (Table 3), the CMV antigenemia was negative in both of these cases.

3.2. Case presentation (patient 7)

A 70-year-old man received a clinical diagnosis of IPF according to the criteria of the American Thoracic Society and European Respiratory Society international statement of March 2009 and was observed without the administration of any medication. Two days before admission, he had a high fever and developed a dry cough. His symptoms worsened, and he was admitted to our hospital in February 2011. His body temperature was 38.4 °C, his respiration rate was 26 breaths/min, and his percutaneous oxygen saturation was 98% on room air. On physical examination, fine crackles were audible at the bases of both lungs. The laboratory findings on admission were as follows: white blood cell count, 6800/mm³; lactate dehydrogenase, 245 IU/L; C-reactive protein, 8.07 mg/dL; and KL-6, 339 U/mL. Chest radiographs showed features of diffuse infiltrates in both lung fields. A high-resolution chest computed tomography showed new diffuse bilateral ground-glass opacities superimposed on a background of reticular opacities and honeycombing, and traction bronchiectasis with basal and peripheral predominance. BALF analysis revealed an increase in neutrophils with no evidence of infectious disease. The patient was treated with steroid pulse therapy (1 g of methylprednisolone per day for 3 days) and antibiotics (meropenem and

| Patient number | Age (y) | Gender | IPF criteria | Pretreatment | WBC (cells/μL) | CRP (mg/dL) | KL-6 (U/mL) |
|----------------|--------|--------|--------------|--------------|----------------|-------------|-------------|
| 1              | 74     | M      | Fulfilled    | None         | 6560           | 14.94       | 962         |
| 2              | 83     | M      | Fulfilled    | None         | 6060           | 1.85        | 3912        |
| 3              | 71     | M      | Fulfilled    | None         | 12,000         | 7.60        | 1688        |
| 4              | 65     | M      | Fulfilled    | None         | 12,510         | 11.58       | 2279        |
| 5              | 59     | M      | Fulfilled    | None         | 6060           | 0.77        | 2525        |
| 6              | 86     | M      | Fulfilled    | None         | 9040           | 3.77        | 1596        |
| 7              | 70     | M      | Fulfilled    | None         | 6800           | 8.07        | 339         |
| 8              | 75     | M      | Not fulfilled| None         | 11,220         | 9.12        | 417         |
| 9              | 60     | M      | Not fulfilled| None         | 11,090         | 5.40        | 429         |
| 10             | 73     | F      | Not fulfilled| None         | 5900           | 0.53        | 425         |
| 11             | 79     | F      | Not fulfilled| None         | 9920           | 10.91       | 1830        |
| 12             | 42     | M      | Not fulfilled| None         | 11,250         | 1.77        | 786         |
| 13             | 78     | M      | Not fulfilled| None         | 5690           | 9.09        | 790         |
| 14             | 58     | F      | Not fulfilled| PSL+CyA      | 9970           | 2.76        | 4767        |

M, male; F, female; SD, standard deviation; IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; WBC, white blood cell; CRP, C-reactive protein; PSL, prednisolone; CyA, cyclosporine A.
pazufloxacin). After treatment, a high-resolution chest computed tomography showed improvement of the ground-grass opacities. After the steroid pulse therapy, the patient was treated with 45 mg of prednisolone per day, and the prednisolone was tapered after 1 month.

4. Discussion

In this study, no viral nucleic acids were detected using PCR in most cases with an acute exacerbation of IPF. Some investigators have studied occult respiratory viral infections in patients with an acute IPF exacerbation. Konishi et al. used gene expression microarrays to characterize an acute IPF exacerbation and did not find any gene expression patterns indicative of a response of the lung to viral infections [9]. Huie et al. reported that BALF and serum obtained from patients with an acute IIP exacerbation and did not find any gene expression patterns indicative of a response of the lung to viral infections [9].

There are no previous reports investigating the association between RSV infection and acute IPF exacerbation. It has been reported that increased levels of circulating proinflammatory cytokines such as interleukin (IL)-1β, IL-8, IL-9, IL-12, and IL-7 and interferon γ are present during an acute IPF exacerbation [14]. IL-1β upregulates IL-8, which is critical for neutrophil recruitment, and the BALF of patients with an acute IPF exacerbation is characterized by neutrophilia [14]. On the other hand, in vitro studies using human bronchiolar epithelial cells, macrophages, and dendritic cells described a complex network of RSV-induced stimulation, inhibition of proinflammatory cytokines, or both. RSV infection in human bronchiolar epithelial cells leads to the production of immune cell-specific chemokines such as IL-8. Early interaction of RSV with several Toll-like receptors on dendritic cells and monocytes releases proinflammatory cytokines such as tumor necrosis factor-α, IL-6, and IL-1β [15]. From these results, it appears that RSV infection-induced proinflammatory cytokines such as IL-1β and IL-8 recruit neutrophils and induce an acute IPF exacerbation.

The PCR for CMV was positive in 2 patients. Some investigators have reported the occurrence of human herpes viral shedding into the alveolar fluid of patients with acute stress [16] and CMV reactivation and infection in patients admitted to an intensive care unit [17]. On the other hand, CMV has been reported to colonize the respiratory tract of immunocompromised patients [18]. In the present study, cytomegalovirus antigenemia was negative in the peripheral blood of patients with a positive PCR for CMV. This result suggests that CMV was not the trigger of exacerbation, but of colonization.

An inverted CD4/8 ratio was seen in 3 patients who had a positive result for a viral infection. A previous report showed that an inverted CD4/8 ratio was seen in patients with viral

---

Table 2 – BALF findings.

| Patient number | Cell count (× 10^3/μL) | Mac (%) | Lym (%) | Neu (%) | Eos (%) | Bas (%) | CD4/8 | Viral separation |
|----------------|------------------------|---------|---------|---------|---------|---------|-------|-----------------|
| 1              | 5.68                   | 28.8    | 57.1    | 11      | 3.1     | 0       | 0.7   | ND              |
| 2              | 6.76                   | 35      | 49      | 1.8     | 14.2    | 0       | 5.28  | ND              |
| 3              | 7.84                   | 72      | 7.6     | 8.2     | 18.7    | 0.5     | 3.49  | ND              |
| 4              | 6.70                   | 32.9    | 31.2    | 31.1    | 4.5     | 0.3     | 2.17  | ND              |
| 5              | 7.28                   | 57.6    | 20.7    | 17.8    | 3.6     | 0.3     | 2.1   | ND              |
| 6              | 6.04                   | 47.4    | 22.5    | 28.4    | 1.4     | 0.3     | 1.5   | ND              |
| 7              | 3.63                   | 74.9    | 2.2     | 22      | 0.9     | 0       | 0.87  | ND              |
| 8              | 3.48                   | 34.3    | 51.9    | 12.8    | 1       | 0       | 4.62  | ND              |
| 9              | 5.54                   | 54      | 38      | 6       | 2       | 0       | 5.06  | ND              |
| 10             | 1.80                   | 55.3    | 33.7    | 3.1     | 7.8     | 0.1     | 2.1   | ND              |
| 11             | 6.56                   | 88.7    | 8.6     | 2.3     | 0.4     | 0       | 2.84  | ND              |
| 12             | 6.38                   | 80.6    | 12      | 7.2     | 0.2     | 0       | 0.85  | ND              |
| 13             | 2.72                   | 72.3    | 17.4    | 4.7     | 4.9     | 0.7     | 5.37  | ND              |
| 14             | 2.96                   | 72.1    | 13.4    | 14      | 0.5     | 0       | 0.2   | ND              |

Mean±SD  5.24±1.86  57.6±19.0  26.1±17.1  12.2±9.2  4.0±4.2  0.2±0.2  2.65±1.75

BALF, bronchoalveolar lavage fluid; Mac, macrophage; Lym, lymphocyte; Neu, neutrophil; Eos, eosinophil; Bas, basophil; ND, not done; SD, standard deviation.
Table 3 - Viral detection by PCR and CMV antigenemia.

| Patient number | hRSV A BR | hRSV A fl | hRSV B | hPIV 1 | hPIV 2 | hPIV 3 | hMPV | CMV | CMV antigenemia |
|----------------|-----------|-----------|--------|--------|--------|--------|------|-----|----------------|
| 1              |           |           |        |        |        |        |      |     |                |
| 2              |           |           |        |        |        |        |      |     |                |
| 3              |           |           |        |        |        |        |      |     |                |
| 4              |           |           |        |        |        |        |      |     |                |
| 5              |           |           |        |        |        |        |      |     |                |
| 6              |           |           |        |        |        |        |      |     |                |
| 7              |           |           |        |        |        |        |      |     |                |
| 8              |           |           |        |        |        |        |      |     |                |
| 9              |           |           |        |        |        |        |      |     |                |
| 10             |           |           |        |        |        |        |      |     |                |
| 11             |           |           |        |        |        |        |      |     |                |
| 12             |           |           |        |        |        |        |      |     |                |

Viral detection by PCR and CMV antigenemia. –

| Patient number | hRSV A | hRSV A fl | hRSV B | hPIV 1 | hPIV 2 | hPIV 3 | hMPV | CMV | CMV antigenemia |
|----------------|--------|-----------|--------|--------|--------|--------|------|-----|----------------|
| 1              |         |           |        |        |        |        |      |     |                |
| 2              |         |           |        |        |        |        |      |     |                |
| 3              |         |           |        |        |        |        |      |     |                |
| 4              |         |           |        |        |        |        |      |     |                |
| 5              |         |           |        |        |        |        |      |     |                |
| 6              |         |           |        |        |        |        |      |     |                |
| 7              |         |           |        |        |        |        |      |     |                |
| 8              |         |           |        |        |        |        |      |     |                |
| 9              |         |           |        |        |        |        |      |     |                |
| 10             |         |           |        |        |        |        |      |     |                |
| 11             |         |           |        |        |        |        |      |     |                |
| 12             |         |           |        |        |        |        |      |     |                |
| 13             |         |           |        |        |        |        |      |     |                |

PCR, polymerase chain reaction; hRSV, human respiratory syncytial virus; hPIV, human parainfluenza virus; hMPV, human metapneumovirus; fl, influenza virus; adeno, human adenovirus; boca, human bocavirus; Rhino, human rhinovirus; CMV, cytomegalovirus; ND, not done.

pneumonia [19,20]. On the other hand, an increased CD4/8 ratio was seen in patients with an acute IPF exacerbation [21]. A CD4/8 ratio would be useful to assess viral infection.

Important limitations of this study include the small number of patients and the possibility of occult viral infections. Furthermore, we performed BAL only during acute exacerbation periods. Therefore, we cannot conclude that the virus in question caused a new infection. Further prospective studies using the same patients in whom the BAL was performed on 2 occasions to evaluate stable IIP and an acute IIP exacerbation are necessary.

5. Conclusion

In summary, we used the PCR method to detect a viral infection in 14 patients with an acute IIP exacerbation. The results of this study suggest that most cases with an acute IIP exacerbation are not caused by a viral infection. Therefore, further studies are necessary to clarify whether a RSV infection induces an acute IIP exacerbation.

Conflict of interest

The authors have no conflicts of interest.

Acknowledgments

The authors would like to thank Dr Mutsuo Yamaya from the Department of Advanced Preventive Medicine for Infectious Disease and Regenerative Medicine, Tohoku University School of Medicine for providing us with human rhinovirus cDNA.

REFERENCES

[1] American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277–304.
[2] American Thoracic Society, European Respiratory. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646–64.
[3] Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993;103:1808–12.
[4] Huie TJ, Olson AL, Cosgrove GP, et al. A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology 2010;15:909–17.
[5] Hiwatari N, Shimura S, Takishima T, et al. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J Exp Med 1994;174:379–86.
[6] Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636–43.
[7] Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility
of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185:1004–14.

[8] Hamano-Hasegawa K, Morozumi M, Nakayama E, et al. Comprehensive detection of causative pathogens using real-time PCR to diagnose pediatric community-acquired pneumonia. J Infect Chemother 2008;14:424–32.

[9] Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;180:167–75.

[10] Wootton SC, Kim DS, Kondoh Y, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:698–702.

[11] Jansen RR, Wieringa J, Koekkoek SM, et al. Frequent detection of respiratory viruses without symptoms: toward defining clinically relevant cutoff values. J Clin Microbiol 2011;49:2631–6.

[12] Avila MM, Carballal G, Rovaletti H, et al. Viral etiology in acute lower respiratory infections in children from a closed community. Am Rev Respir Dis 1989;140:634–7.

[13] Borg I, Rohde G, Löseke S, et al. Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. Eur Respir J 2003;21:944–51.

[14] Oishi K, Mimura-Kimura Y, Miyasho T, et al. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine 2013;61:84–9.

[15] Walsh EE. Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 2011;32:423–32.

[16] van den Brink JW, Simoons-Smit AM, Beishuizen A, et al. Respiratory herpes simplex virus type 1 infection/colonisation in the critically ill: marker or mediator? J Clin Virol 2004;30:68–72.

[17] Papazian L, Fraisse A, Garbe L, et al. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology 1996;84:280–7.

[18] Heurlin N, Brattström C, Lönnqvist B, et al. Aetiology of pulmonary diseases in immunocompromised patients. Eur Respir J 1991;4:10–8.

[19] Myou S, Fujimura M, Yasui M, et al. Bronchoalveolar lavage cell analysis in measles viral pneumonia. Eur Respir J 1993;6:1437–42.

[20] Nomura F, Shimokata K, Sakai S, et al. Cytomegalovirus pneumonitis occurring after allogeneic bone marrow transplantation: a study of 106 recipients. Jpn J Med 1990;29:595–602.

[21] Ambrosini V, Cancellieri A, Chilosi M, et al. Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003;22:821–6.